Chemotherapy-induced cognitive impairment in women with breast cancer: A critique of the literature

Oncology Nursing Forum

Volumn 32, Issue 2, 2005, Pages 329-342

  Jansen, Catherine E ^a,b   Miaskowski, Cristine ^a   Dodd, Marylin ^a   Dowling, Glenna ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; COGNITIVE DEFECT; FEMALE; HUMAN; INFORMED CONSENT; MENOPAUSE; METHODOLOGY; MIDDLE AGED; PSYCHOLOGICAL ASPECT; REPRODUCIBILITY; REVIEW; RISK FACTOR; SELF CARE; SURVIVOR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COGNITION DISORDERS; FEMALE; HUMANS; INFORMED CONSENT; MENOPAUSE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; RISK FACTORS; SELF CARE; SURVIVORS;

EID: 33645792884     PISSN: 0190535X     EISSN: 15380688     Source Type: Journal    
DOI: 10.1188/05.ONF.329-342     Document Type: Review

References (44)

1. Ahles, T.A., Saykin, A.J., Furstenberg, C.T., Cole, B., Mott, L.A., Skalla, K., et al. (2002). Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. Journal of Clinical Oncology, 20, 485-493.
2. Ahles, T.A., Saykin, A.J., Noll, W.W., Furstenberg, C.T., Guerin, S., Cole, B., et al. (2003). The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psycho-Oncology, 12, 612-619.
3. Aikin, J. (1995). Menopausal symptoms resulting from breast cancer therapies. Innovations in Breast Cancer Care, 1, 2-5, 21.
4. Anderson-Hanley, C., Sherman, M.L., Riggs, R., Agocha, V.B., & Compas, B.E. (2003). Neuropsychological effects of treatments for adults with cancer: A meta-analysis and review of the literature. Journal of the International Neuropsychological Society, 9, 967-982.
5. Bender, C.M., Paraska, K.K., Sereika, S.M., Ryan, C.M., & Berga, S.L. (2001). Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: A critical review. Journal of Pain and Symptom Management, 21, 407-424.
6. Brezden, C.B., Phillips, K.A., Abdolell, M., Bunston, T., & Tannock, I.F. (2000). Cognitive function in breast cancer patients receiving adjuvant chemotherapy. Journal of Clinical Oncology, 18, 2695-2701.
7. Cole, R.P., Scialla, S.J., & Bednarz, L. (2000). Functional recovery in cancer rehabilitation. Archives of Physical Medicine and Rehabilitation, 81, 623-627.
8. Copeland, D.R., Fletcher, J.M., Pfefferbaum-Levine, B., Jaffe, N., Ried, H., & Maor, M. (1985). Neuropsychological sequelae of childhood cancer in long-term survivors. Pediatrics, 75, 745-753.
9. Copeland, D.R., Moore, B.D., III, Francis, D.J., Jaffe, N., & Culbert, S.J. (1996). Neuropsychologic effects of chemotherapy on children with cancer: A longitudinal study. Journal of Clinical Oncology, 14, 2826-2835.
10. Cowley, L., Heyman, B., Stanton, M., & Milner, S.J. (2000). How women receiving adjuvant chemotherapy for breast cancer cope with their treatment: A risk management perspective. Journal of Advanced Nursing, 31, 314-321.
11. Cull, A., Hay, C., Love, S.B., Mackie, M., Smets, E., & Stewart, M. (1996). What do cancer patients mean when they complain of concentration and memory problems? British Journal of Cancer, 74, 1674-1679.
12. Cutter, W.J., Norbury, R., & Murphy, D.G. (2003). Oestrogen, brain function, and neuropsychiatric disorders. Journal of Neurology, Neurosurgery, and Psychiatry, 74, 837-840.
13. Erlanger, D.M., Kutner, K.C., & Jacobs, A.R. (1999). Hormones and cognition: Current concepts and issues in neuropsychology. Neuropsychology Review, 9, 175-207.
14. Fairclough, D.L., Fetting, J.H., Cella, D., Wonson, W., & Moinpour, C.M. (1999). Quality of life and quality adjusted survival for breast cancer patients receiving adjuvant therapy. Quality of Life Research, 8, 723-731.
15. Freeman, J.R., & Broshek, D.K. (2002). Assessing cognitive dysfunction in breast cancer: What are the tools? Clinical Breast Cancer, 3(Suppl. 3), S91-S99.
16. Ganz, P. (1998). Cognitive dysfunction following adjuvant treatment of breast cancer: A new dose-limiting toxic effect? Journal of the National Cancer Institute, 90, 182-183.
17. Ganz, P.A. (2000). Quality of life across the continuum of breast cancer care. Breast Journal, 6, 324-330.
18. Gazzaniga, M.S., Ivry, R.B., & Mangun, G.R. (2002). Cognitive neuroscience: The biology of the mind (2nd ed.). New York: W.W. Norton and Company.
19. Grober, S.E. (2002). Resources for treatment of chemotherapy-related cognitive difficulty. Cancer Practice, 10, 216-218.
20. Haan, M.N., Shemanski, L., Jagust, W.J., Manolio, T.A., & Kuller, L. (1999). The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA, 282, 40-46.
21. Hebben, N., & Milberg, W. (2002). Essentials of neuropsychological assessment. New York: Wiley and Sons.
22. Heilman, K.M., Valenstein, E., & Watson, R.T. (1997). Disorders of attention. In M.R. Trimble & J.L. Cummings (Eds.), Contemporary behavioral neurology (pp. 127-137). Boston: Butterworth-Heinemann.
23. Jemal, A., Murray, T., Ward, E. Samuels, A., Tiwari, R.C., Ghafoor, A., et al. (2005). Cancer statistics, 2004. CA: A Cancer Journal for Clinicians, 55, 10-30.
24. Knobf, M.T. (1998). Natural menopause and ovarian toxicity associated with breast cancer therapy. Oncology Nursing Forum, 25, 1519-1530.
25. Kun, L.E., Mulhern, R.K., & Crisco, J.J. (1983). Quality of life in children treated for brain tumors: Intellectual, emotional, and academic function. Journal of Neurosurgery, 58, 1-6.
26. Lezak, M.D., Howieson, D.B., & Loring, D.W. (2004). Neumpsychological assessment (4th ed.). New York: Oxford University Press.
27. Marina, N. (1997). Long-term survivors of childhood cancer. The medical consequences of cure. Pediatric Clinics of North America, 44, 1021-1042.
28. Moore, I.M., Kramer, J., &Ablin, A. (1986). Late effects of central nervous system prophylactic leukemia therapy on cognitive functioning. Oncology Nursing Forum, 13(4), 45-51.
29. Olin, J.J. (2001). Cognitive function after systemic therapy for breast cancer. Oncology, 15, 613-618.
30. O'Shaughnessy, J. (2003). Chemotherapy-related cognitive dysfunction in breast cancer. Seminars in Oncology Nursing, 19(4, Suppl. 2), 17-24.
31. Padmanabhan, N., Wang, D.Y., Moore, J.W., & Rubens, R.D. (1987). Ovarian function and adjuvant chemotherapy for early breast cancer. European Journal of Cancer Clinical Oncology, 23, 745-748.
32. Polit, D.F., & Hungler, B.P. (1999). Nursing research: Principles and methods (6th ed.). Philadelphia: Lippincott.
33. Reger, M., Welsh, R., Razani, J., Martin, D.J., & Boone, K.B. (2002). A metaanalysis of the neuropsychological sequelae of HIV infection. Journal of the International Neumpsychological Society, 8, 410-424.
34. Ryan, C.M., Morrow, L.A., Bromet, E.J., & Parkinson, D.K. (1987). Assessment of neuropsychological dysfunction in the workplace: Normative data from the Pittsburgh Occupational Exposures Test Battery. Journal of Clinical and Experimental Neuropsychology, 9, 665-679.
35. Schagen, S.B., Muller, M.J., Boogerd, W., Rosenbrand, R.M., van Rhijn, D., Rodenhuis, S., et al. (2002). Late effects of adjuvant chemotherapy on cognitive function: A follow-up study in breast cancer patients. Annals of Oncology, 13, 1387-1397.
36. Schagen, S.B., van Dam, F.S., Muller, M.J., Boogerd, W., Lindeboom, J., & Bruning, P.F. (1999). Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer, 85, 640-650.
37. Sherwin, B.B. (1996). Hormones, mood, and cognitive functioning in postmenopausal women. Obstetrics and Gynecology, 87(2, Suppl.), 20S-26S.
38. Sherwin, B.B. (1998). Estrogen and cognitive function in women. Proceedings of the Society for Experimental Biology and Medicine, 217, 17-22.
39. Spreen, O., & Strauss, E. (1998). A compendium of neuropsychological tests. Administration, norms, and commentary New York: Oxford University Press.
40. Tchen, N., Juffs, H.G., Downie, F.P, Yi, Q.L., Hu, H., Chemerynsky, I., et al. (2003). Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. Journal of Clinical Oncology, 21, 4175-4183.
41. van Dam, F.S., Schagen, S.B., Muller, M.J., Boogerd, W., v.d. Wall, E., Droogleever Fortuyn, M., et al. (1998). Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: High-dose versus standard-dose chemotherapy. Journal of the National Cancer Institute, 90, 210-218.
42. Wefel, J.S., Lenzi, R., Theriault, R.L., Davis, R.N., & Meyers, C.A. (2004). The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma. Results of a prospective, randomized, longitudinal trial. Cancer, 100, 2292-2299.
43. Wieneke, M.M., & Dienst, E.R. (1995). Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-Oncology, 4, 61-66.
44. Yaffe, K., Cauley, J., Sands, L., & Browner, W. (1997). Apolipoprotien E phenotype and cognitive decline in a prospective study of elderly community women. Archives of Neurology, 54, 1110-1114.